Procter & Gamble Health Ltd
Procter & Gamble Health Q2 FY23 earnings call: Revenue & Margins
Q2 FY23 investor presentation: what the company reported on revenue, margins and projects.
Based on Procter & Gamble Health Ltd's Q2 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The provided pages from the presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor do they mention year-on-year changes or any explicit outlook for revenue or volumes. The presentation pages provided do not contain any EBITDA, operating margin, profit after tax (PAT), year-on-year changes, or explicit margin outlook figures for the quarter.
From Procter & Gamble Health Ltd's Q2 FY23 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
2 more points management made on revenue & sales performance
Profitability & Margins
See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Procter & Gamble Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹370 Cr, net profit ₹95 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Procter & Gamble Health Ltd's management said in earlier quarters
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q2 FY23 results?
The provided pages from the presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor do they mention year-on-year changes or any explicit outlook for revenue or volumes. The presentation pages provided do not contain any EBITDA, operating margin, profit after tax (PAT), year-on-year changes, or explicit margin outlook figures for the quarter.
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 27.4 with a market cap of ₹9,135 Cr. Investors should review the full earnings analysis for detailed insights.
Is Procter & Gamble Health Ltd planning capital expenditure?
The investor presentation does not mention any specific capital expenditure (capex), capacity expansion, or new plant/project details including amounts, status, or timelines.
Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.